Squarepoint’s PDS Biotechnology PDSB Stock Holding History

Squarepoint’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37,200	Closed	-$49.5K	–	4831
2025 Q2	$49.5K	Hold	37,200	–	–	﹤0.01%	4307
2025 Q1	$44.3K	Buy	+37,200	New	+$52.9K	﹤0.01%	4359

Other funds holding PDSB

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Squarepoint's PDSB Position: Q1 2026 in Review

Squarepoint sold out of PDS Biotechnology (PDSB) in Q1 2026, closing a stake of 192,556 shares — an estimated $148K sold.

Squarepoint first reported a position in PDSB in Q1 2023 and held it in 8 quarters. The position peaked at $631K in Q1 2023. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

Squarepoint reported no remaining PDS Biotechnology position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 192,556 PDS Biotechnology shares in Q1 2026, an estimated $148K.
Squarepoint first reported a position in PDS Biotechnology in Q1 2023 and held it in 8 quarters.
Squarepoint's PDS Biotechnology position peaked at $631K in Q1 2023.
41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.